DUCHENNE MUSCULAR DYSTROPHIN (DMD)

Clinical trials for DUCHENNE MUSCULAR DYSTROPHIN (DMD) explained in plain language.

Never miss a new study

Get alerted when new DUCHENNE MUSCULAR DYSTROPHIN (DMD) trials appear

Sign up with your email to follow new studies for DUCHENNE MUSCULAR DYSTROPHIN (DMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

CRISPR treatment shows promise in rare muscle disease

Disease control Completed

This early-phase trial tested a CRISPR-based gene therapy (HG302) in 4 boys aged 4 to 8 with Duchenne muscular dystrophy (DMD), a severe muscle-wasting disease. The therapy aims to restore the missing dystrophin protein in muscle cells using a single intravenous injection. The ma…

Matched conditions: DUCHENNE MUSCULAR DYSTROPHIN (DMD)

Phase: EARLY_PHASE1 • Sponsor: HuidaGene Therapeutics Co., Ltd. • Aim: Disease control

Last updated May 06, 2026 16:13 UTC

DUCHENNE MUSCULAR DYSTROPHIN (DMD)

Get alerted when new DUCHENNE MUSCULAR DYSTROPHIN (DMD) trials appear

CRISPR treatment shows promise in rare muscle disease